Medical artificial intelligence (AI) specialist AIDOT announced its foray into the global market by participating in the world's largest IT exhibition, CES, as a Korean company within the Gangwon-do Pavilion. The company showcased its flagship solutions, Cerviray AI (an AI diagnostic solution for cervical cancer) and URO dot AI (an AI diagnostic solution for urinary stones).
During the CES exhibition, AIDOT focused on introducing AI diagnostic technologies that are practical in real clinical settings. They highlighted how image-based AI can simultaneously support medical professionals' decision-making while enhancing both diagnostic accuracy and efficiency.
Cerviray AI is an AI solution that analyzes cervical images and visually presents the risk level of lesions in the cervix, uniquely classifying them into four stages: Normal, CIN1, CIN2/3, and CANCER. It is specifically focused on improving the accuracy of early detection and screening for cervical cancer.
A key highlight that garnered significant interest in the global health sector was the emphasis on the solution's structural usability. It has been developed to provide AI results even in resource-limited or medically underserved environments without an internet connection.
The simultaneously unveiled URO dot AI is an AI solution that automatically analyzes the position, size, and quantity of urinary stones based on CT scans.
Its strength lies in reducing the workload for medical staff in urology clinical environments where repeated readings are necessary, and in providing more consistent diagnostic results.
AIDOT emphasized that this technology is already being used in actual clinical settings, highlighting the differentiation as 'medical AI that has moved beyond research use and entered the real-world application stage.'
The AIDOT booth saw active discussions with medical professionals and technology partners from various regions, including North America, the Middle East, Asia, and Central and South America. Discussions covered actual application cases, regulatory response strategies, and business models tailored to local medical environments. The company confirmed its global expansion potential, particularly with inquiries about national-level health projects and the possibility of introducing the solutions into public healthcare systems.
An AIDOT official stated, "CES is an important stage to show how medical AI connects with actual clinical sites beyond just a technology demonstration. Through Cerviray AI and URO dot AI, we have clearly presented to the global market that AI diagnostics can become the standard of medical care."
Moving forward, AIDOT plans to leap forward as a global medical AI company by expanding its AI solutions into various image-based diagnostic areas beyond cervical cancer and urinary stones to include conditions like otitis media, and by pursuing certification and partnership strategies tailored to the regulatory environment of each country.
Hankyung TV / January 7, 2026 / Reporter Yang Jae-jun
